CompletedPhase 2

Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's Disease

Lead sponsor

Merck Sharp & Dohme LLC

Asset

MK0677

Listed sites

Recruiting sites

Enrollment

512

actual

Study population

Alzheimer’s disease

Key I/E criterion

•Alzheimer's disease

Primary endpoint

•Cognitive function

Identifiers

Registered as

Org study ID0677-030

Secondary2006_412

SecondaryFormally-BG0812AZ

SecondaryMK0677-030

NCT IDNCT00074529

Timeline

Milestones

Study start2003-10 (month precision)

Study first posted2003-12-16estimated

Primary completion2006-01actual (month precision)

Study completion2006-01actual (month precision)

Last update posted2015-07-24estimated

Assets

Drug assets

MK0677

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years

SexAll

Healthy volunteersNot accepted

Eligibility criteria

•Patients must have probable Alzheimer's disease of mild or moderate severity.

•A brain scan and laboratory results must be consistent with Alzheimer's disease.

•The patient must be otherwise medically healthy.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Global cognition

2 endpoints

Primary/protocol endpoint

Cognitive function over 12 month period; safety and tolerability

Time frame:over 12 month period

descriptive

Secondary/protocol endpoint

AD symptoms over a 6 month and 12 month period measured by the CIBIC + and the ADAS-Cog.

Time frame:over a 6 month and 12 month period

ADAS-Cog

descriptive

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.